Vistagen to present ph94b exploratory phase 2a research program for adjustment disorder with anxiety at american society for clinical psychopharmacology annual meeting

South san francisco--(business wire)--vistagen therapeutics, inc. (nasdaq: vtgn) (vistagen), a late clinical-stage, central nervous system (cns)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other cns disorders, today announced that the clinical trial abstract for its exploratory phase 2a clinical study in adjustment disorder with anxiety (ajda) for ph94b, its investigational rapid-onset pherine nasal spray with
VTGN Ratings Summary
VTGN Quant Ranking